AAC Accepts, published online ahead of print on 26 February 2007
Antimicrob. Agents Chemother. doi:10.1128/AAC.01447-06
Copyright © 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

1
2
3 # Selective Phosphorylation of Antiviral Drugs by Vaccinia Virus Thymidine Kinase
4
5
6
7 Running title: selective phosphorylation by vaccinia virus TK
8
9
10
11
12
13
14 Mark N. Prichard[1*], Kathy A. Keith[1], Mary P. Johnson[1], Emma A. Harden[1],
15 Alexis McBrayer[1], Ming Luo[2], Shihong Qiu[2], Debasish Chattopadhyay[2], Xuesen
16 Fan[3], Paul F. Torrence[3], and Earl R. Kern[1]
17
18
19
20
21
22 Departments of Pediatrics[1] and Microbiology[2], University of Alabama School of
23 Medicine, Birmingham AL, 35233 USA; Department of Chemistry and Biochemistry,
24 Northern Arizona University, Flagstaff, AZ 86011 USA[3].
25
26
27
28 *Corresponding author. Mailing address: 128 Children's Harbor Building, 1600 6th Ave. South,
29 Birmingham, AL 35233 USA. Phone (205) 934-1995. Fax: (205) 975-1992. E-mail:
30 mprichard@peds.uab.edu.
31

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 ABSTRACT

2

3 The antiviral activity of a new series of thymidine analogs was determined against
4 vaccinia virus (VV), cowpox virus (CV), herpes simplex virus, and varicella zoster virus.
5 Several compounds were identified that had good activity against each of the viruses
6 including a set of novel 5-substituted deoxyuridine analogs. To investigate the possibility
7 that these drugs might be phosphorylated preferentially by the viral thymidine kinase
8 (TK) homologs, the antiviral activity of these compounds were also assessed using TK
9 deficient strains of some of these viruses. Some of these compounds were shown to be
10 much less effective in the absence of a functional TK gene in CV, which was unexpected
11 given the high degree of amino acid identity between this enzyme and its cellular
12 homolog. This unanticipated result suggested that the CV TK was important in the
13 mechanism of action of these compounds and also that it might phosphorylate a wider
14 variety of substrates than other type II enzymes. To confirm these data, we expressed the
15 VV TK and human TK1 in bacteria and isolated the purified enzymes. Enzymatic assays
16 demonstrated that the viral TK could efficiently phosphorylate many of these compounds,
17 whereas most of the compounds were very poor substrates for the cellular kinase, TK1.
18 Thus, the specific phosphorylation of these compounds by the viral kinase may be
19 sufficient to explain the TK dependence. This unexpected result suggests that selective
20 phosphorylation by the viral kinase may be a promising new approach in the discovery of
21 highly selective inhibitors of orthopoxvirus replication.

22

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 **Introduction**

2 Effective therapies for orthopoxvirus infections are required to combat potential
3 infections of variola virus or monkeypox virus and also to treat adverse events associated
4 with vaccination with vaccinia virus (VV) (7, 8, 26). Cidofovir (CDV) exhibits good
5 antiviral activity against a wide spectrum of orthopoxviruses including VV, cowpox virus
6 (CV), variola virus, ectromelia virus, and monkeypox virus (3, 18, 35, 43, 51). There is
7 also a small body of clinical experience using CDV to treat molloscum contagiosum and
8 orf virus infections (15, 27). Thus, CDV is a potentially useful drug for the treatment of
9 orthopoxvirus infections and there is an Investigational New Drug Approval for the
10 emergency treatment of smallpox and complications from vaccination. Unfortunately,
11 the utility of this compound is limited by the lack of oral bioavailability and inherent
12 toxicity reduces its usefulness in the clinic (13).

13 Recent advances in the development of therapeutics for these infections have
14 identified a number of highly active compounds (52). Among these, inhibitors of the VV
15 I7L proteinase have been identified that block virion maturation (9). Inhibitors of the p37
16 major envelope protein (F13L) are also good inhibitors of viral replication both in vitro
17 and in vivo (54). Ether lipid analogs of cidofovir have also been shown to be orally
18 bioavailable and highly effective inhibitors of orthpoxvirus infection both in vitro and in
19 vivo (35, 36, 38). The thymidine analog, (*N*)-methanocarbathymidine ((*N*)-MCT), is also
20 active against orthopoxviruses both in vitro and in vivo and its activity appears to be
21 dependent on a functional orthopoxvirus TK gene (45). This mechanism of action has
22 historically proven to be extraordinarily effective in the therapy of herpesvirus infections,

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 so we sought to identify other potential nucleoside analogs that could be selectively
2 phosphorylated by this viral enzyme.

3 While herpesviruses and orthopoxviruses both express proteins with TK activity (39,
4 40), the enzymes are distinct in several fundamental respects, including molecular
5 weight, quaternary structure, and substrate specificity. Herpesvirus enzymes belong to
6 the type I family of TKs, whereas the VV TK is a type II enzyme (5). The type I enzyme
7 encoded by the herpes simplex virus *UL23* gene (42), is active as a homodimer and is
8 unaffected by allosteric effectors (34). This enzyme, like other members of this family,
9 can phosphorylate a broad range of substrates including thymidine, 2'-deoxycytidine, and
10 many synthetic nucleoside analogs (20, 25, 34). The prototypic type II TK is encoded by
11 the J2R gene in VV and is closely related to the human cytosolic TK1, which is also a
12 member of this family (32). This group of enzymes are active as homotetramers (31) and
13 are allosterically controlled by both dTTP and dTDP (6, 30). Members of this family are
14 also characterized by a very narrow substrate specificity limited to thymidine and a few
15 closely related analogs.

16 Early studies by Prusoff and coworkers identified a number of 5-substituted 2'-
17 deoxyuridine analogs, such as idoxuridine (IDU) and trifluoridine, which exhibited
18 antiviral activity (28). Although some of these compounds were associated with
19 significant toxicity, they could selectively inhibit the replication of both herpes simplex
20 virus (HSV) (1, 11, 12), and VV (33, 44). Early studies with VV demonstrated that IDU
21 competed with thymidine as a substrate for the DNA polymerase, and was incorporated
22 in viral DNA (48). Interestingly, a functional TK was apparently involved in the
23 mechanism of action of the drug since recombinant viruses that did not express this

ACCEPTED
Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 enzyme were comparatively resistant to its activity (10). HSV was also sensitive to this
2 compound and similarly required a functional virus TK for activity (25). Subsequent
3 studies identified related compounds, such as brivudin, that were remarkably active
4 against HSV, yet did not exhibit the toxicity of earlier compounds (16, 17). Like IDU,
5 these compounds derive their remarkable specificity through selective phosphorylation
6 by herpesvirus TK homologs, and remained unactivated in uninfected cells since they are
7 not substrates for cellular nucleoside kinases (55). However, these compounds were
8 inactive against the orthopoxviruses since they were not phosphorylated by the viral type
9 II TK homologs and were not converted to active metabolite.

10 Recently, a new series of deoxyuridine analogs with large substituents at the 5
11 position were described that retained activity against both VV and CV (21-24). Here, we
12 report that the compounds exhibit an unexpected TK dependence in orthopoxviruses.
13 Enzymatic assays demonstrated that these novel compounds were good substrates for the
14 VV TK, whereas they were poor substrates for the human homolog, TK1. These results
15 suggest that although these enzymes are closely related, selective activation of antiviral
16 drugs by the VV TK is a viable approach in the discovery of highly specific drugs to treat
17 orthopoxvirus infections. Studies presented here were designed to describe the unique
18 substrate specificity of the VV TK in an effort to develop better antiviral drugs for the
19 treatment of orthopoxvirus infections.

20

21 MATERIALS AND METHODS

22 **Cells, viruses, and drugs.** Methods for obtaining and passaging human foreskin
23 fibroblast (HFF) cells were described previously (49). Culture medium for all cell lines

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

was Minimal Essential Medium (MEM) containing 10% fetal bovine serum (FBS) and standard concentrations of L-glutamine, penicillin and gentamicin. VV strains WR, Copenhagen, and IHD, were obtained from American Type Culture Collection (ATCC, Manassas, VA). Working stocks of these viruses were propagated in Vero cells obtained from the ATCC. CV strain Brighton, was kindly provided by John W. Huggins (Department of Viral Therapeutics, Virology Division, U.S. Army Medical Research Institute of Infectious Disease, Frederick, Md.). CV strains delta crmA (TK^+) and TK:GFP lacZ (TK^-) were obtained from Pete Turner (University of Florida, Gainesville, FL) and were described previously (2). The *wt* HSV-1 strain F and the TK deficient DM2.1, as well as the *wt* HSV-2 strain MS and the TK altered strain AG-3 were described and propagated as reported previously (29). CDV (Vistide®) was a gift from Mick Hitchcock (Gilead Sciences Inc., Foster City, CA) and other compounds were either purchased (Sigma Chemical company, St Louis, MO) or were provided through the NIAID, NIH, Bethesda MD. Substituted 2' deoxyuridine derivatives were synthesized in the lab of Paul Torrence and are: (**1**) 5-(2,2-dicyanovinyl)-2'-deoxyuridine; (**2**) 5-(2-carboxyethyl-2-cyanovinyl)-2'-deoxyuridine; (**3**) 5-(2-amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-yl)-1-(2-deoxypento-furanosyl)-pyrimidine-2,4(1H,3H)-dione; (**4**) 1-(2-deoxypentofuranosyl)-5-[(3-methyl-5-oxo-1-phenyl-4,5-dihydro-4H-pyrazol-4-ylidene)pyrimidine-2,4(1H,3H)-dione; (**5**) 5-[bis(3-methyl-5-oxo-1-phenyl-4,5-dihydro-4H-pyrazol-4-yl)methyl-1-(2-deoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione; (**6**) 5-(2-amino-3-cyano-5-oxo-6,6-dimethyl-5,6,7,8-tetrahydro-4H-chromen-4-yl)-1-(2-deoxypento-furanosyl)-pyrimidine-2,4(1H,3H)-dione.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

VV, CV and HSV plaque reduction assays. For assays against VV and CV, HFF cells were added to 6-well plates and incubated for two days at 37ºC with 5% CO_2 and 90% humidity. On the day of assay, drug at two times the final desired concentration was diluted serially 1:5 in 2X MEM with 10% FBS to provide six concentrations. Aspiration of culture medium from triplicate wells for each drug concentration was followed by addition of 0.2 ml per well of diluted virus which would give 20-30 plaques per well in MEM containing 10% FBS or 0.2 ml medium for drug toxicity wells. The plates were incubated for one h with shaking every 15 minutes. An equal amount of 1% agarose was added to an equal volume of each drug dilution and this mixture was added to each well in 2 ml volumes and the plates incubated for three days. The cells were stained with a solution of 0.01% neutral red in phosphate buffered saline (PBS) and incubated for 5-6 h. The stain was aspirated, and plaques counted using a stereomicroscope at 10X magnification and 50% effective concentration (EC_{50}) values were calculated by standard methods. The HSV plaque reduction assays were essentially the same as for VV and CV with the following changes. The drug solutions were prepared at the desired concentration in MEM with 2% FBS and a liquid overlay with pooled human serum containing antibodies to HSV instead of agarose was used. At 72 h following infection, the media containing the drug was aspirated and the monolayers were stained with 1 ml of a solution of 0.01% crystal violet in 60% methanol for 10 min. Residual stain was then washed from the wells with 1 ml PBS and plaques were counted. VZV assays were performed in the same manner, except the plaques were stained at 10 days following infection.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

CV β-galactosidase assay. Monolayers of HFF cells in 96-well plates were incubated at 37°C for 24 h in a humidified incubator. Drugs were then diluted in the plates and either TK^+ or TK^- strains of CV were added at a multiplicity of infection of 0.05 PFU/cell. At 48 h post infection, the media was removed and the β-galactosidase substrate, chlorophenol red-ß-galactopyranoside, was added at a final concentration of 50 µg/ml in PBS. The conversion of the colorimetric substrate was determined by measuring the absorbance at 570 nm and EC_{50} values were calculated by standard methods (46). The EC_{50} ratio for TK^- and TK^+ viruses, respectively, was calculated and used as a measure of TK dependence.

Cytotoxicity determination. HFF cells were added to 96 well black-walled plates at a concentration of 2.5 x 10^4 cells per well. After 24 h, the media was aspirated and 125 µl of each drug concentration in MEM with 2% FBS was added to the first row of wells in triplicate. Serial 1:5 dilutions were performed using the Beckman BioMek Liquid Handling System. After compound addition, the plates were incubated for 7 days in a 5% CO_2 incubator at 37ºC. To each well 35 µl of CellTiter-Glo® (Promega, Madison, WI) reagent was added and luminescence activity was measured with a luminometer. Standard methods were used to determine the drug concentration which inhibited cell proliferation by 50% (IC_{50}).

Enzyme preparation: The full length open reading frame for the TK encoded by the WR strain of VV and a cDNA encoding human TK1 were amplified and cloned into pET15b (Novagen, Madison, WI) and pET151 d vector (Invitrogen, Carlsbad, CA), respectively to an amino terminal HIS tags. Primers for amplifying J2R were, 5'-CAC CAT GAA CGG CGG ACA TAT TC-3' and 5'-TGA GTC GAT GTA ACA CTT TCT

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

ACCEPTED

TAA-3', and primers for amplifying TK1 were 5'-CAC CAT GAG CTG CAT TAA CCT GCC CAC t-3' and 5'-CTA GTT GGC AGG GCT GCA TT-3'. These plasmids were transformed into *E. coli* strain BL21 (DE3) (Invitrogen), grown to exponential phase (OD_{600} of 0.4-0.6) and induced with 0.5mM IPTG (isopropyl-β-D-thiogalactopyranoside Sigma) at 37ºC for 4 h. Cells were collected by centrifugation and pellets were stored at -80ºC. Pellets were thawed on ice and resuspended in enzyme lysis buffer consisting of 50mM Tris pH 8.0, 500mM NaCl, 2mM $MgCl_2$, 2mM imidazole, 0.05% Tween-20, 10% sucrose, 1mg/ml lysozyme, and protease inhibitor cocktail (Sigma Chemical Company, St. Louis, MO). Samples were incubated on ice for 30 min and sonicated (10 x 6 second bursts), 0.5mg/ml DNase I from bovine pancreas (Sigma Chemical Company) was added to the lysate and incubated an additional 15 min on ice. The lysate was clarified by centrifugation for 30 min at 25,000 rpm. Ni-NTA agarose beads (Qiagen, Germantown, MD) were equilibrated in lysis buffer and added to the supernatant. The agarose bead suspension was agitated for 2 h at 4° C and then loaded onto a column for subsequent purification steps. The column was washed with 10 bed volumes of wash buffer (20mM Tris, 500mM NaCl, 2mM $MgCl_2$, 20mM imidazole, 0.5% Tween-20). Proteins were eluted with 5 bed volumes of elution buffer (20mM Tris pH 8.0, 500mM NaCl, 2mM $MgCl_2$, 250mM imidazole, 0.05% Tween-20) aliquoted and stored at -80ºC. The proteins were analyzed by SDS-PAGE to assess purity. Higher molecular weight species were observed in the human TK1 preparation, so mass spectrometry was used to identify these proteins. This analysis identified these products as human TK1 and is consistent with multimeric forms of the enzyme. This analysis also identified one contaminating bacterial protein (b2255, gi16130190) that is of unknown function, but is not homologous

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

to any known kinases. It also does not exhibit detectable ATPase activity since the concentrated enzyme did not significantly degrade ATP in one h of incubation.

Enzyme Activity Assays. Kinetic parameters for substrates of TK1 and VV TK were determined by measuring ATP utilization with a luciferase based assay. Briefly, substrates were diluted in black clear bottom 96 well plates in buffer containing 20 mM HEPES pH 7.4, 250 mM NaCl, 2 mM Dithiothreitol (DTT), 1 mM $MgCl_2$ and 50 µM ATP. Reactions were initiated by the addition of the purified enzyme and the mixtures were incubated at room temperature for 1h after which the Kinase-Glo® luciferase reagent (Promega) was added. The resulting luminescence was used to measure the quantity of residual ATP in the reaction. Reactions were linear over 90 min and were dependent on the addition of dThd, or other suitable substrates.

RESULTS

Antiviral activity and TK dependence in orthopoxviruses. Recently described 5-substituted deoxyuridine analogs that were shown to possess antiviral activity are related in that they have rather bulky substituents in the 5 position of the pyrimidine ring (Fig. 1). These compounds proved to be very active against VV and CV in plaque assays and were relatively nontoxic (Table 1). We hypothesized that these compounds might be selective inhibitors of orthopoxvirus replication because they were preferentially phosphorylated by the viral TK homologs. A recently reported TK dependence assay was used to see if the presence of the CV TK homolog affected the activity of the compounds (47). In this assay, the CDV negative control was equally effective against the TK^+ and TK^- strains of the virus since it is a monophosphate analog and does not require the first phosphorylation step (Table 1). By contrast, the IDU positive control

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 requires an initial phosphorylation by the viral kinase and consequently was much less
2 active in a TK$^-$ strain as reported previously (10). In this series of experiments, each of
3 the analogs was more than 20-fold less active in the TK$^-$ strain and suggested that they
4 required the viral TK for optimal activity. This unexpected result was intriguing since it
5 suggested that the orthopoxvirus TK activity expressed in infected cells might be able to
6 confer sensitivity to antiviral drugs in that same manner as the herpesvirus TK homologs
7 impart sensitivity to acyclovir.

8 **Antiviral activity against herpesviruses.** The TK dependence observed in the
9 first set of experiments prompted an examination of the efficacy of these compounds
10 against herpesviruses, which also express enzymes with TK activity. This series of drugs
11 was evaluated against HSV-1, HSV-2, and VZV using standard plaque assays. Each of
12 these compounds had good antiviral activity against wt strains of HSV-1, HSV-2, and
13 VZV (Table 2). These compounds were also tested in TK deficient strains of HSV-1 and
14 HSV-2 to see if the drugs also exhibited TK dependence in these viruses. Only
15 compound 5 was substantially less effective in the TK negative strains of these viruses.
16 These contrasts with the results obtained with CV and suggest that other viral targets may
17 also be involved in the mechanism of action of these compounds in herpesviruses.

18 **Purification of VV TK and characterization of its enzymatic activity.** The TK
19 dependence observed in CV suggested that this enzyme was important in the mechanism
20 of action of these new drugs. We hypothesized that the viral TK might be activating the
21 drugs directly. To test this hypothesis, we wanted to determine the relative
22 phosphorylation efficiency of these substrates by human TK1 and J2 in VV. The VV
23 enzyme was selected rather than the CV kinase since it is more closely related to the

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 enzyme expressed by variola virus. And since the CV and VV kinases are 98% identical
2 at the amino level, they might be expected to exhibit similar activity. Both VV TK and
3 human TK1 were expressed in bacteria and the histidine tagged enzymes were purified to
4 see if the viral enzyme selectively phosphorylated these compounds. Enzymatic activity
5 was determined in an ATP utilization assay using luciferase as a reporter. For VV TK,
6 we demonstrated that the utilization of ATP was dependent on thymidine or idoxuridine
7 as phosphate acceptors and reactions were linear over the 60 min assay period (Fig. 2A).
8 Assays were also optimized with respect to pH (Fig. 2B), salt concentration, and Mg^{++}
9 requirements (data not shown). The enzyme required Mg^{++} and concentrations of salt
10 over 100 mM reduced its activity, while the pH optimum was approximately 9. A
11 previous report identified dTTP and dTDP as allosteric affectors of the enzyme (30). We
12 confirmed the allosteric inhibition with dTTP with the new assay, and also observed
13 >50% inhibition of enzymatic activity for dUTP concentrations greater than 60 μM (Fig.
14 2C). The assay was reproducible and Lineweaver-Burke plots for thymidine also yielded
15 K_m values between 13 and 49 μM (Fig. 2D, Tables 3,4). K_m values were confirmed in a
16 standard spectrophotometric assay (50) and an isothermal calorimetry assay that directly
17 measures the heat of binding of the substrate to the enzyme and generated values of 27
18 and 24 μM, respectively (Torrence and Smith, unpublished data). These values agree
19 well with the reported value of 15 μM value for the human TK1 homolog purified from
20 *E. coli*, which occurs predominantly as dimers (4). These data suggested that the assay
21 conditions were suitable for assessing the kinetic parameters of other potential substrates.
22 Human TK1 was also purified by similar methods (Fig. 2E). Higher molecular weight
23 species were observed and were confirmed by mass spectrometry to be TK1, consistent

ACCEPTED
Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

with multimers of this enzyme. Kinase assays with this enzyme yielded similar results to those described for the viral enzyme including thymidine dependent ATP utilization, reactions that were linear over the assay period and Km values were similar to those reported in the literature (Fig. 2F) (4).

A series of known pyrimidine analogs were assayed with purified VV TK and human TK1 to further characterize this system. The viral enzyme appeared to phosphorylate dThd, IDU, and bromodeoxyuridine with similar efficiencies, while the phosphorylation of fluorodeoxyuridine appeared to be somewhat less efficient (Table 3). Trifluridine (TFT) and fialuridine (FIAU) appeared to be superior substrates for the VV TK, whereas the cytidine analog, fiacitabine (FIAC) was not a substrate for the viral enzyme. Human TK1 also appeared to phosphorylate most of the substrates with comparable efficiencies, with the single exception of FIAU. This drug had a significantly lower K_m with the viral TK as compared to TK1 suggesting that it was a better substrate for the viral enzyme (Table 1). The efficiency with which the viral enzyme phosphorylates this compound was also more than 6-fold higher than that observed with TK1. This selective phosphorylation by the viral enzyme is also consistent with the previously reported activity of this compound against VV and CV (37). The potential phosphorylation of several other compounds was also evaluated in this system, but did not appear to be suitable substrates, including CDV, acyclovir, penciclovir, ganciclovir, brivudin, and sorivudine (data not shown). These results demonstrate that in many respects, the substrate specificities of these enzymes are related, but also that there are significant differences that might be exploited in the discovery of new antiviral agents.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 **5-substituted deoxyuridine derivatives as substrates for VV TK and TK1.**
2 The TK dependence exhibited by the compounds in Table 1 suggested that the CV TK
3 was important for their antiviral activity. To test the hypothesis that this might be
4 mediated through selective phosphorylation by the viral TK, we determined their kinetic
5 parameters using purified VV TK and human TK1 (Table 4). This analysis confirmed
6 that all six analogs were substrates for the viral TK and many of them had K_m values that
7 were similar to thymidine, the natural substrate for this enzyme. Compounds 1, 2, and 4
8 were phosphorylated with the highest efficiency. These results contrast with those
9 obtained with the cellular enzyme where only compounds 1 and 2 were substrates, and
10 these had K_m values that exceeded 100 μM and were not phosphorylated efficiently. Of
11 interest, four analogs were phosphorylated by the viral TK with efficiencies that were 10
12 fold greater than those measured for TK1. Compound 4 appeared to be one of the best
13 substrates for the viral kinase and its phosphorylation efficiency was 34-fold higher for
14 the viral enzyme. This result is consistent with the TK dependence data where this
15 compound also exhibited the greatest TK dependence (Table 1). Since the viral enzyme
16 preferentially phosphorylates this series of deoxyuridine analogs as well as FIAU, we
17 conclude that the substrate specificity of the viral enzyme is broader than had been
18 suspected, and is distinct from that of TK1. These data taken together with the TK
19 dependence data, suggest that selective phosphorylation is important in the mechanism of
20 action of these compounds and that orthopoxvirus TK homologs can confer specificity to
21 this series of compounds.

22 **Predicted Structure of J2**. The distinct substrate specificity of the J2R kinase
23 was interesting since this enzyme is so closely related to the human homolog, TK1.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 Although the conserved domains in these proteins share 70% identity at the amino acid
2 level, there are regions where they diverge (Fig. 3). To see if these regions might be near
3 the substrate recognition site, we modeled the structure of this enzyme based on an amino
4 acid alignment with four crystal structures of other TKs, including human (PDB ID
5 1XBT and 1W4R), *Clostridium Acetobutylicum* (PDB ID 1XX6) and, *Ureaplasma*
6 *parvum* (PDB ID 2B8T). Each of these structures is a type II enzyme and would be
7 predicted to be structurally related. The identity was 70, 37, and 35 percent between the
8 conserved domains of the viral enzyme, human, *Clostridium Acetobutylicum*, and
9 *Ureaplasma parvum* TKs, respectively. The coordinates of human TK 1XBT were used
10 as the template to model VV TK, using the program Modeller (41). Since the identity
11 between the conserved domains of the two proteins is 70% (Fig. 3), the reliability of the
12 model for VV TK is high. The active site residues are rather well conserved, suggesting
13 the enzyme specificity of VV TK is similar to that of human TK. This is consistent with
14 results obtained for most compounds in this report; however significant differences were
15 observed also and may be related to the subtle differences between the two enzymes.
16 One potentially important difference is a substitution of a slightly smaller serine residue
17 for the threonine 163 in TK1 that is in close contact with the 5 methyl group in
18 thymidine. Another difference is the conformation of the side chain of residue Arg45
19 (Fig. 4). In the crystal structure 1XBT, the human TK is in complex with the allosteric
20 inhibitor dTTP (53) where side chain of its active site arginine (Arg60) coordinates with
21 the triphosphate of the inhibitor. The loop next to this arginine (residues 61 to 74) is
22 disordered in this structure. The homologous Arg45 in VV TK was modeled without the
23 bound inhibitor and this amino acid is located within the space to be occupied by dTTP if

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

present. The conformation of the loop next to Arg45 (residues 46 to 59) was modeled in VV TK (Fig. 4). This loop contains seven residues with significant differences to those in the human TK (blue highlighted white text in the consensus line of Fig. 3). The difference in this loop may offer an opportunity for exploitation of VV TK specific substrates, especially the five residues (47-51) next to Arg45. Moieties representing modifications of the triphosphate of dTTP may result in selective binding to VV TK. Residues within 12 Å of the active site (highlighted in gray in the consensus line of Fig. 3) may also contribute to the selectivity of a potential inhibitor of VV TK. In the human TK1 structure the binding pocket is rather open around the 3' and 4' carbons of the deoxyribose portion of the molecule (53). Thus by extension, it may be possible to modify this region of the molecule to increase its selectivity of the viral enzyme, which appears to be born out by the selective phosphorylation of FIAU which has a fluorine in the 2' position of an arabinose sugar. After this manuscript was submitted, the crystal structure of the VV TK was determined by us, and was also reported by another laboratory (19). The model presented here is very close to the actual structure for the enzyme and continued efforts with compounds crystallized in the active site will help define the molecular basis of the observed differences in substrate specificity.

Discussion

Experiments summarized here described the antiviral activity of a new series of 5-substituted pyrimidine analogs against selected orthopoxviruses and herpesviruses. These data led us to conduct additional experiments examining the mechanism of action of these compounds. Results from these studies suggested that i) VV TK can selectively phosphorylate deoxyuridine nucleosides with rather large substituents at the 5 position, ii)

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

ACCEPTED

1 the phosphorylation of these drugs by orthopoxvirus TK homologs is important in the
2 mechanism of action of these compounds, and iii) the strategy of selective
3 phosphorylation can be used in the discovery of new inhibitors against orthopoxviruses.
4 These results were unexpected, inasmuch as TK1 shares a high degree of amino acid
5 identity with the VV homolog and were thought to share a similarly narrow substrate
6 specificity (53). They are also important because selective phosphorylation has proven to
7 be one of the most successful strategies for the treatment of herpesvirus infections.
8 Indeed, the treatments of choice for HSV, VZV, Epstein-Barr virus, and cytomegalovirus
9 infections each rely on a viral encoded enzyme to selectively phosphorylate the drugs,
10 and this activation is required for the compounds to be metabolized to the active form
11 that inhibits the viral DNA polymerase. Unfortunately, these compounds are not active
12 in orthopoxvirus infections, primarily because the initial phosphorylation step is not
13 catalyzed by the TK homologs in these viruses (47). This view is supported by a
14 previous report in which VV became fully sensitive to acyclovir when the herpes simplex
15 virus TK homolog was supplied in *trans* to activate the drug (14). Thus, a strategy of
16 improving the selective activation of nucleosides could be used to improve the efficacy of
17 drug candidates. Results presented here also support this idea and demonstrate that
18 selective phosphorylation is a feasible strategy for orthopoxviruses.

19 The activation of the compounds by the VV TK suggests that the substrate
20 specificities of the VV TK and TK1 are sufficiently different for such a strategy to be
21 effective. The modeled structure of this enzyme suggests that there are a few amino acid
22 differences near the active site of these two enzymes that may contribute to the broader
23 substrate specificity observed with the viral enzyme. In this regard, solving the three

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

dimensional structure of this enzyme should facilitate the design of new inhibitors that are better substrates for the viral kinase and this project is well underway. This information will represent an important step in the development of even more selective and effective pyrimidine analogs for use in treating orthopoxviruses that relies on the selective activation by the viral kinase, resulting in a highly effective and nontoxic drug. In this endeavor it will also be important to consider differences in the J2R homologs in other orthopoxviruses, particularly variola and monkeypox that each have 5 amino acid substitutions compared to VV (http://www.poxvirus.org/data.asp). Of particular interest are the E153T and E156K polymorphisms in variola, compared to VV since each of these amino acids is predicted to lie within 12 Å of the active site of the bound dTTP inhibitor. Also of interest, will be the coordinates of substrates co-crystallized in the active site of the enzymes. These and other similar experiments remain on the critical path of development of these and related compounds.

The TK dependence observed with this series of compounds in CV taken together with the preferential phosphorylation by the VV TK are consistent and suggest a mechanism of action for this series of compounds. We propose that the viral TK activates these compounds by catalyzing the addition of the alpha phosphate on these compounds. Subsequent phosphorylation events by viral or cellular enzymes further phosphorylate the compound to the level of the triphosphate, which in turn inhibits the viral DNA polymerase. Studies presented here do not directly demonstrate the addition of a phosphate to the 5' position of these compounds and it remains possible that some other metabolite is the active form and that viral DNA synthesis is inhibited indirectly through the inhibition of thymidylate synthetase or other cellular targets. It is also

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

possible that these compounds are also substrates for other kinases including the mitochondrial thymidine kinase, TK2, or even the thymidylate kinase encoded by VV and that other phosphorylation steps are also important in the mechanism of action of these compounds. Nevertheless, the TK dependence data in CV suggests that the viral TK exerts a major influence on the activity of the compounds regardless of the final target of the inhibitors. Data in favor of our proposed mechanism of action including direct phosphorylation of the drugs are; i) the compounds are analogs of known substrates that are phosphorylated by the VV TK, ii) the luminescent TK assays presented require a phosphate acceptor for the hydrolysis of ATP and each of the compounds exhibit this property, iii) the ITC study demonstrated direct binding of the compounds to the enzyme, iv) the compounds require the viral TK to be active in vitro, and v) the potent inhibition of DNA synthesis by each of the analogs (EC_{50} values of less than 2 μM) is consistent with direct inhibition of the DNA polymerase by triphosphate metabolites. Further experiments are required to identify the active metabolites and the final target of these compounds.

Perhaps the most significant aspect of these studies is how they affect the perception of the potential of the orthopoxvirus TK homologs to play a role in the therapy of these infections. The data presented here suggest that the orthopoxvirus and herpesviruses TK homologs can each be used in a common approach towards the development of specific antiviral therapies. While neither enzyme is required for viral replication, both can be exploited by drugs used to inhibit the replication of these viruses. To be sure, the range of substrates that the VV TK will phosphorylate is more restricted than those phosphorylated by the herpesvirus TK homologs, and the TK dependence in

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

herpesviruses is more robust than that seen in the orthopoxviruses, but opportunities remain. Additional experiments may identify better substrates for the kinase that have the potential to be highly selective therapies for the treatment of orthopoxvirus infections.

ACKNOWLEDGMENTS

We thank Geraldine Jefferson, Shalisa Sanders, and Robin Conley for their expert technical assistance. These studies were supported by Public Health Service contract NO1-AI-30049 and grant 1-U54-AI-057157 from the NIAID, NIH. The authors also acknowledge contract USAMRIID DAMD 17-03-C-0081(PFT) from the US Army Medical Research Materiel Command and the State of Arizona Proposition 301 Funds (PFT) for financial support, and Robert Smith for excellent technical assistance.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

Table 1. Antiviral activity against orthopoxviruses.

Compound	Efficacy EC_{50}[a] (µM) Vaccinia	Cowpox	TK dependence[b] (µM) TK^-	TK^+	TK^-/TK^+ Ratio	Toxicity[c] (µM)
1	17 ± 6.4	21 ± 12	46 ± 15	1.9 ± 0.6	23 ± 1.2	180 ± 73
2	18 ± 14	11 ± 9.2	71 ± 25	1.9 ± 0.5	35 ± 9.3	>300 ± 0
3	4.6 ± 2.0	2.0 ± 0.3	67 ± 6	1.9 ± 0.2	36 ± 4.6	200 ± 11
4	6.9 ± 0.9	5.6 ± 5.2	73 ± 1.2	0.9 ± 0.2	84 ± 14	159 ± 13
5	11 ± 1.0	9.0 ± 7.0	51 ± 0	2.7 ± 1.7	23 ± 12	>234 ± 58
6	7.9 ± 2.5	8.4 ± 3.6	67 ± 0	3.1 ± 2.4	38 ± 32	>233 ± 96
IDU	5.6 ± 0.2	1.8 ± 0.2	76 ± 8.4	1.1 ± 0.3	75 ± 15	>293 ± 0
CDV	11 ± 3.8	32 ± 7.5	16 ± 12	10 ± 3.5	1.9 ± 1.9	>317 ± 0

a. Effective concentrations that reduced plaque formation by 50% (EC_{50}). Some values were reported previously (22).
b. EC_{50} values were determined in beta galactosidase assays in TK^- and TK+ strains of cowpox virus as described previously (47).
c. Cytotoxicity was determined by CellTiter-Glo® assays (Promega) with SD values shown.

Table 2. Antiviral activity against herpes simplex virus and varicella zoster virus.

Compound	Efficacy EC_{50}[a] (µM) HSV-1 TK^+ (E-377)[b]	HSV-1 TK^- (DM2.1)[b]	HSV-2 TK^+ (MS)[b]	HSV-2 TK^- (AG-3)[b]	VZV (Ellen)[b]
1	11 ± 0.3	14 ± 4.6	11 ± 2.6	12 ± 4.6	15 ± 1.5
2	7.6 ± 0.8	16 ± 5.7	8.3 ± 2.6	11 ± 1.1	48 ± 11
3	8.6 ± 4.8	13 ± 1.3	12 ± 3.5	12 ± 4.4	16 ± 11
4	7.9 ± 5.5	9.6 ± 2.9	4.2 ± 2.6	7.6 ± 0.9	15 ± 4.5
5	7.9 ± 0.3	25 ± 6.0	10 ± 0.7	39 ± 12	10 ± 1.8
6	7.3 ± 1.9	17 ± 0.6	13 ± 5.3	14 ± 2.9	9.2 ± 3.8
ACV	1.3 ± 0	>444 ± 0	3.1 ± 0	>444 ± 0	8.5 ± 6.3

a. EC_{50}, effective concentration that reduced plaque formation by 50%.
b. Virus strains used were described previously (47).

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1
2 Table 3. Kinetic parameters for substrates of VV TK and human TK1 using known
3 antiviral agents

	VV TK			Human TK1		
Substrate	K_m (μM)[a]	V_{max} (μM min^{-1} mg^{-1})	V_{max}/K_m[b]	K_m (μM)[a]	V_{max} (μM min^{-1} mg^{-1})	V_{max}/K_m[b]
dThd	49 ± 7.6	289 ± 137	5.9	60 ± 13	619 ± 70	10
BrDU	30. ± 6.2	281 ± 59	9.4	46 ± 0	573 ± 62	12
IDU	31 ± 4.7	222 ± 58	7.2	38 ± 11	577 ± 26	15
FDU	113 ± 85	108 ± 63	0.96	96 ± 11	472 ± 22	5
TFT	14 ± 4.3	333 ± 44	24	47 ± 2.8	545 ± 68	12
FIAU	4.3 ± 2.5	99 ± 41	22.7	66 ± 3.5	233 ± 6	3.5
FIAC	>135	<0.14	<0.001	>135	<25	<0.19
CDV	>158	<0.025	<0.0002	>159	<25	<0.16

4 a. Average of three or more determinations with standard deviations shown.
5 b. Calculated efficiency using 0.5 μg of purified VV TK and TK1 in each assay.
6

7
8 Table 4. Kinetic parameters for substrates of VV TK and human TK1 using new
9 experimental compounds.

	VV TK			Human TK1		
Substrate	K_m (μM)[a]	V_{max} (μM min^{-1} mg^{-1})[a]	V_{max}/K_m[b]	K_m (μM)[a]	V_{max} (μM min^{-1} mg^{-1})[a]	V_{max}/K_m[b]
1	9.6 ± 5.5	120 ± 46	12	113 ± 20	130 ± 65	1.2
2	13 ± 5.2	119 ± 6	9	118 ± 14	98 ± 21	0.8
3	103 ± 2.9	91 ± 33.4	0.9	>200	<55	<0.28
4	11 ± 7.9	106 ± 7	9.6	>200	<55	<0.28
5	21 ± 1.1	91 ± 3	4.3	>200	<55	<0.28
6	97 ± 26	78 ± 7	0.8	>200	<55	<0.28
dThd	21 ± 12	302 ± 7	15	23 ± 13	334 ± 192	14.5
CDV	>200	<55	<0.28	>200	<55	<0.28

10 a. Average of three or more determinations with standard deviations shown.
11 b. Calculated efficiency using 0.5 μg of purified VV TK and TK1 in each assay.
12

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

ACCEPTED

1 Figure 1.



2
3
4
5
6
7
8
9
10
11

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 Figure 2.



2
3

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

Figure 3.

```
                   1                                                 50
      Cowpox    (1) ---------------MNGGHIQLIIGPMFSGKSTELIRRVRRYQIAQYKC
    Vaccinia    (1) ---------------MNGGHIQLIIGPMFSGKSTELIRRVRRYQIAQYKC
     Variola    (1) ---------------MNGGHIQLIIGPMFSGKSTELIRRVRRYQIAQYKC
   human TK1    (1) MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKC
   Consensus    (1)                MNGGHIQLIIGPMFSGKSTELIRRVRRYQIAQYKC
                   51                                               100
      Cowpox   (36) VTIKYSNDNRYGTGLWTHDKNNFAALEATKLYDVLESITDFSVIGIDEGQ
    Vaccinia   (36) VTIKYSNDNRYGTGLWTHDKNNFEALEATKLCDVLESITDFSVIGIDEGQ
     Variola   (36) VTIKYSNDNRYGTGLWTHDKNNFEALEATKLCDVLEAITDFSVIGIDEGQ
   human TK1   (51) LVIKYAKDTRYSSSFCTHDRNTMEALPACLLRDVAQEALGVAVIGIDEGQ
   Consensus   (51) VTIKYSNDNRYGTGLWTHDKNNFEALEATKLCDVLESITDFSVIGIDEGQ
                   101                                              150
      Cowpox   (86) FFPDIVEFCERMANEGKIVIVAALDGTFQRKPFNNILNLIPLSEMVVKLT
    Vaccinia   (86) FFPDIVEFCERMANEGKIVIVAALDGTFQRKPFNNILNLIPLSEMVVKLT
     Variola   (86) FFPDIVEFCERMANEGKIVIVAALDGTFQRKPFNNILDLIPLSEMVVKLT
   human TK1  (101) FFPDIVEFCEAMANAGKTVIVAALDGTFQRKPFGAILNLVPLAESVVKLT
   Consensus  (101) FFPDIVEFCERMANEGKIVIVAALDGTFQRKPFNNILNLIPLSEMVVKLT
                   151                                              200
      Cowpox  (136) AVCMKCFKEASFSKRLGAETEIEIIGGNEMYQSVCRKCYIDS--------
    Vaccinia  (136) AVCMKCFKEASFSKRLGEETEIEIIGGNDMYQSVCRKCYIDS--------
     Variola  (136) AVCMKCFKEASFSKRLGTETKIEIIGGIDMYQSVCRKCYIDS--------
   human TK1  (151) AVCMECFREAAYTKRLGTEKEVEVIGGADKYHSVCRLCYFKKASGQPAGP
   Consensus  (151) AVCMKCFKEASFSKRLGTETEIEIIGGNDMYQSVCRKCYIDS
                   201                              234
      Cowpox  (178) ----------------------------------
    Vaccinia  (178) ----------------------------------
     Variola  (178) ----------------------------------
   human TK1  (201) DNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN
   Consensus  (201)
```

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 Figure 4



2
3
4
5

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 **FIGURE LEGENDS**

2 Figure 1.

3 Structures of 5- substituted deoxyuridine analogs. Compounds 1-6 are analogs of

4 deoxyuridine and contain the substitutions shown.

5 Figure 2.

6 Characteristics of the enzymatic activity of J2 TK and human TK1. (A) ATP

7 utilization by VV TK was dependent on either 100 µM thymidine (filled circles), or 100

8 µM idoxuridine (open squares), while no ATP was consumed in the absence of a

9 nucleoside substrate (open circles). (B) Thymidine dependent utilization of ATP by VV

10 TK was determined at pH 6, 7, 8, 9, and 10. Luciferase activity was measured following

11 a kinase reaction in the presence (dark gray bars) and absence of 50 µM thymidine (light

12 gray bars). (C) VV TK enzymatic activity was determined in the presence of the

13 potential allosteric affector molecules shown. Shaded circles and open circles represent

14 dTTP and dUTP, respectively, while shaded squares represent the control without added

15 inhibitors. Open triangles, shaded triangles, and open squares represent dGTP, dCTP,

16 and dATP, respectively. (D) A Lineweaver-Burke plot for thymidine as a substrate of

17 VV TK. (E) Coomassie stained gels of purified J2 TK and human TK1. Higher

18 molecular weight species indicated by asterisks in the human TK1 lane were identified as

19 TK1 by mass spectrometry and are consistent with multimers. One contaminating

20 bacterial protein was also identified as indicated by the † symbol and is a bacterial

21 protein of unknown function (b2255, gi16130190). (F) Enzymatic assays for both the J2

22 (filled circles) and TK1 (open squares) are linear with time and both require thymidine or

23 a related substrate for ATP utilization.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 Figure 3.

2 Alignment of amino acid sequences for selected TK homologs. Amino acid
3 sequences of TK homologs are shown for cowpox virus (NP_619890), vaccinia virus
4 (YP_232976), variola virus (NP_042123), and human TK1 (AAH07986) with the
5 consensus sequence shown below. In the consensus line, text in dark blue boxes
6 represents the significant differences in the loop next to the active site residue Arg45.
7 Text highlighted in gray denotes amino acid differences within 12 Å of the bound
8 inhibitor dTTP.

9 Figure 4.

10 Model of VV TK structure derived from crystal structure 1XBT by blastp
11 (www.ncbi.nlm.nih.gov). Modeled J2R TK structure is shown in magenta overlayed on
12 the reported structure of human TK1 1XBT (green). The modeled side chain of Arg45
13 (yellow) was shown to overlap with the bound dTTP in 1XBT. Orange dots represent the
14 amino acid differences near the active site. The drawing was performed with program
15 PyMol (San Carlos, CA: Delano Scientific) (2002)).

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

REFERENCES

1. **Albert, D. M., M. Lahav, P. N. Bhatt, T. W. Reid, R. E. Ward, R. C. Cykiert, T. S. Lin, D. C. Ward, and W. H. Prusoff.** 1976. Successful therapy of herpes hominis keratitis in rabbits by 5-iodo-5'-amino-2'5'-dideoxyuridine (AIU): a novel analog of thymidine. Invest Ophthalmol **15:**470-8.
2. **Ali, A. N., P. C. Turner, M. A. Brooks, and R. W. Moyer.** 1994. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology **202:**305-14.
3. **Baker, R. O., M. Bray, and J. W. Huggins.** 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res **57:**13-23.
4. **Berenstein, D., J. F. Christensen, T. Kristensen, R. Hofbauer, and B. Munch-Petersen.** 2000. Valine, not methionine, is amino acid 106 in human cytosolic thymidine kinase (TK1). Impact on oligomerization, stability, and kinetic properties. J Biol Chem **275:**32187-92.
5. **Black, M. E., and D. E. Hruby.** 1992. A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase. J Biol Chem **267:**9743-8.
6. **Black, M. E., and D. E. Hruby.** 1992. Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding. J Biol Chem **267:**6801-6.
7. **Bray, M.** 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res **58:**101-14.
8. **Breman, J. G., and D. A. Henderson.** 2002. Diagnosis and management of smallpox. N Engl J Med **346:**1300-8.
9. **Byrd, C. M., T. C. Bolken, A. M. Mjalli, M. N. Arimilli, R. C. Andrews, R. Rothlein, T. Andrea, M. Rao, K. L. Owens, and D. E. Hruby.** 2004. New class of orthopoxvirus antiviral drugs that block viral maturation. J Virol **78:**12147-56.
10. **Byrd, C. M., and D. E. Hruby.** 2004. Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus. Methods Mol Biol **269:**31-40.
11. **Cheng, Y. C., B. Goz, and W. H. Prusoff.** 1975. Deoxyribonucleotide metabolism in Herpes simplex virus infected HeLa cells. Biochim Biophys Acta **390:**253-63.
12. **Cheng, Y. C., J. P. Neenan, B. Goz, D. C. Ward, and W. H. Prusoff.** 1975. Synthesis and biological activity of some novel analogs of thymidine. Ann N Y Acad Sci **255:**332-41.
13. **Cundy, K. C., Z. H. Li, M. J. Hitchcock, and W. A. Lee.** 1996. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos **24:**738-44.
14. **Darby, G., B. A. Larder, K. F. Bastow, and H. J. Field.** 1980. Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells. J Gen Virol **48:**451-4.
15. **Davies, E. G., A. Thrasher, K. Lacey, and J. Harper.** 1999. Topical cidofovir for severe molluscum contagiosum. Lancet **353:**2042.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 16. **De Clercq, E.** 1993. Antiviral agents: characteristic activity spectrum depending
2 on the molecular target with which they interact. Adv Virus Res **42:**1-55.
3 17. **De Clercq, E.** 1980. Antiviral and antitumor activities of 5-substituted 2'-
4 deoxyuridines. Methods Find Exp Clin Pharmacol **2:**253-67.
5 18. **De Clercq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C.**
6 **Maudgal.** 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature
7 **323:**464-7.
8 19. **El Omari, K., N. Solaroli, A. Karlsson, J. Balzarini, and D. K. Stammers.**
9 2006. Structure of vaccinia virus thymidine kinase in complex with dTTP:
10 insights for drug design. BMC Struct Biol **6:**22.
11 20. **Elion, G. B.** 1983. The biochemistry and mechanism of action of acyclovir. J
12 Antimicrob Chemother **12 Suppl B:**9-17.
13 21. **Fan, X., X. Zhang, L. Zhou, K. A. Keith, E. R. Kern, and P. F. Torrence.**
14 2006. 5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with
15 anti-orthopoxvirus activity. J Med Chem **49:**3377-82.
16 22. **Fan, X., X. Zhang, L. Zhou, K. A. Keith, E. R. Kern, and P. F. Torrence.**
17 2006. Assembling a smallpox biodefense by interrogating 5-substituted
18 pyrimidine nucleoside chemical space. Antiviral Res **71:**201-5.
19 23. **Fan, X., X. Zhang, L. Zhou, K. A. Keith, E. R. Kern, and P. F. Torrence.**
20 2006. A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-
21 orthopoxvirus activity. Bioorg Med Chem Lett **16:**3224-8.
22 24. **Fan, X., X. Zhang, L. Zhou, K. A. Keith, M. N. Prichard, E. R. Kern, and P.**
23 **F. Torrence.** 2006. Toward orthopoxvirus countermeasures: a novel
24 heteromorphic nucleoside of unusual structure. J Med Chem **49:**4052-4.
25 25. **Field, H., A. McMillan, and G. Darby.** 1981. The sensitivity of acyclovir-
26 resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis
27 **143:**281-5.
28 26. **Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson.**
29 2003. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis
30 **37:**251-71.
31 27. **Geerinck, K., G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, Y.**
32 **Vanrenterghem, H. Degreef, and B. Maes.** 2001. A case of human orf in an
33 immunocompromised patient treated successfully with cidofovir cream. J Med
34 Virol **64:**543-9.
35 28. **Goz, B., and W. H. Prusoff.** 1970. Pharmacology of viruses. Annu Rev
36 Pharmacol **10:**143-70.
37 29. **Hartline, C. B., E. A. Harden, S. L. Williams-Aziz, N. L. Kushner, R. J.**
38 **Brideau, and E. R. Kern.** 2005. Inhibition of herpesvirus replication by a series
39 of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res **65:**97-
40 105.
41 30. **Hruby, D. E.** 1985. Inhibition of vaccinia virus thymidine kinase by the distal
42 products of its own metabolic pathway. Virus Res **2:**151-6.
43 31. **Hruby, D. E., and L. A. Ball.** 1982. Mapping and identification of the vaccinia
44 virus thymidine kinase gene. J Virol **43:**403-9.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

1 32. **Hruby, D. E., R. A. Maki, D. B. Miller, and L. A. Ball.** 1983. Fine structure
2 analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene.
3 Proc Natl Acad Sci U S A **80:**3411-5.
4 33. **Jack, M. K., and R. W. Sorenson.** 1963. Vaccinial keratitis treated with IDU.
5 Arch Ophthalmol **69:**730-2.
6 34. **Jamieson, A. T., and J. H. Subak-Sharpe.** 1974. Biochemical studies on the
7 herpes simplex virus-specified deoxypyrimidine kinase activity. J Gen Virol
8 **24:**481-92.
9 35. **Keith, K. A., M. J. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern.** 2003.
10 Evaluation of nucleoside phosphonates and their analogs and prodrugs for
11 inhibition of orthopoxvirus replication. Antimicrob Agents Chemother **47:**2193-8.
12 36. **Keith, K. A., W. B. Wan, S. L. Ciesla, J. R. Beadle, K. Y. Hostetler, and E. R.**
13 **Kern.** 2004. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and
14 cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents
15 Chemother **48:**1869-71.
16 37. **Kern, E. R.** 2003. In vitro activity of potential anti-poxvirus agents. Antiviral Res
17 **57:**35-40.
18 38. **Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle,**
19 **and K. Y. Hostetler.** 2002. Enhanced inhibition of orthopoxvirus replication in
20 vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents
21 Chemother **46:**991-5.
22 39. **Kit, S., D. R. Dubbs, and M. Anken.** 1967. Altered properties of thymidine
23 kinase after infection of mouse fibroblast cells with herpes simplex virus. J Virol
24 **1:**238-40.
25 40. **Kit, S., L. J. Piekarski, and D. R. Dubbs.** 1963. Induction of thymidine kinase
26 by vaccinia-infected mouse fibroblasts. J Mol Biol **6:**22-33.
27 41. **Marti-Renom, M. A., A. C. Stuart, A. Fiser, R. Sanchez, F. Melo, and A. Sali.**
28 2000. Comparative protein structure modeling of genes and genomes. Annu Rev
29 Biophys Biomol Struct **29:**291-325.
30 42. **McGeoch, D. J., M. A. Dalrymple, A. J. Davison, A. Dolan, M. C. Frame, D.**
31 **McNab, L. J. Perry, J. E. Scott, and P. Taylor.** 1988. The complete DNA
32 sequence of the long unique region in the genome of herpes simplex virus type 1.
33 J Gen Virol **69 (Pt 7):**1531-74.
34 43. **Neyts, J., H. Sobis, R. Snoeck, M. Vandeputte, and E. De Clercq.** 1993.
35 Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-
36 dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine
37 cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur
38 J Clin Microbiol Infect Dis **12:**269-79.
39 44. **Neyts, J., E. Verbeken, and E. De Clercq.** 2002. Effect of 5-iodo-2'-
40 deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob
41 Agents Chemother **46:**2842-7.
42 45. **Prichard, M. N., K. A. Keith, D. C. Quenelle, and E. R. Kern.** 2006. Activity
43 and mechanism of action of N-methanocarbathymidine against herpesvirus and
44 orthopoxvirus infections. Antimicrob Agents Chemother **50:**1336-41.
45 46. **Prichard, M. N., and C. Shipman, Jr.** 1990. A three-dimensional model to
46 analyze drug-drug interactions. Antiviral Res **14:**181-205.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest

47. **Prichard, M. N., A. D. Williams, K. A. Keith, E. A. Harden, and E. R. Kern.** 2006. Distinct thymidine kinases encoded by cowpox virus and herpes simplex virus contribute significantly to the differential antiviral activity of nucleoside analogs. Antiviral Res **71:**1-6.
48. **Prusoff, W. H., Y. S. Bakhle, and J. F. McCrea.** 1963. Incorporation Of 5-Iodo-2'-Deoxyuridine Into The Deoxyribonucleic Acid Of Vaccinia Virus. Nature **199:**1310-1.
49. **Rybak, R. J., C. B. Hartline, Y. L. Qiu, J. Zemlicka, E. Harden, G. Marshall, J. P. Sommadossi, and E. R. Kern.** 2000. In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob Agents Chemother **44:**1506-11.
50. **Schelling, P., G. Folkers, and L. Scapozza.** 2001. A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates. Anal Biochem **295:**82-7.
51. **Stittelaar, K. J., J. Neyts, L. Naesens, G. van Amerongen, R. F. van Lavieren, A. Holy, E. De Clercq, H. G. Niesters, E. Fries, C. Maas, P. G. Mulder, B. A. van der Zeijst, and A. D. Osterhaus.** 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature **439:**745-8.
52. **Tseng, C.K.** 2005. Overview of antiviral drug discovery and development. in, Antiviral drug discovery for emerging diseases and bioterrorism threats. Torrence, P.F. (Ed.). Wiley-Interscience, Hoboken, N.J.
53. **Welin, M., U. Kosinska, N. E. Mikkelsen, C. Carnrot, C. Zhu, L. Wang, S. Eriksson, B. Munch-Petersen, and H. Eklund.** 2004. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A **101:**17970-5.
54. **Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan.** 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol **79:**13139-49.
55. **Zou, F. C., G. E. Dutschman, E. De Clercq, and Y. C. Cheng.** 1984. Differential binding affinities of sugar-modified derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine for herpes simplex virus-induced and human cellular deoxythymidine kinases. Biochem Pharmacol **33:**1797-800.

ACCEPTED

Downloaded from http://aac.asm.org/ on November 16, 2019 by guest